Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd. has entered into a strategic licensing agreement with Gilead Sciences to manufacture and distribute the HIV-1 treatment drug Lenacapavir in India and 120 other countries. This move aims to make the innovative treatment more accessible and affordable in regions with high HIV burden, aligning with Dr. Reddy’s commitment to impacting 1.5 billion patients by 2030. The agreement also includes potential future commercialization for HIV prevention if clinical trials and approvals are successful.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
